Merck & Co New: (NYSE: MRK)
$47.75
-0.05 (-0.11%)
Volume 11,626,578
Jun 18 04:00 PM ET
Zacks Rank: 3-Hold 
| #3 |
Full Company Report
Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service.
General Information
MERCK & CO INC
ONE MERCK DRIVE P.O. BOX 100
WHITEHOUSE STATION, NJ 08889-0100
Phone: 908-423-4840
Fax: 908-735-1253
Web: http://www.merck.com
Email: NA
| Industry | LARGE CAP PHARMA |
| Sector | Medical |
| Fiscal Year End | December |
| Last Reported Quarter | 03/31/2013 |
| Next EPS Date | 07/26/2013 |
Price and Volume Information
| Zacks Rank |  |
| Yesterday's Close | 47.80 |
| 52 Week High | 50.16 |
| 52 Week Low | 38.72 |
| Beta | 0.59 |
| 20 Day Moving Average | 26,682,592.00 |
| Target Price Consensus | 50.79 |
% Price Change
| 4 Week | 5.73 |
| 12 Week | 9.41 |
| YTD | 17.12 |
Share Information
| Shares Outstanding (millions) | 3,019.61 |
| Market Capitalization (millions) | 144,337.45 |
| Short Ratio | 1.50 |
| Last Split Date | 02/17/99 |
% Price Change Relative to S&P 500
| 4 Week | 7.49 |
| 12 Week | 3.58 |
| YTD | 2.68 |
Dividend Information
| Dividend Yield | 3.60% |
| Annual Dividend | $1.72 |
| Payout Ratio | 0.47 |
| Change in Payout Ratio | 0.02 |
| Last Dividend Payout / Amount | 06/13/2013 / $0.43 |
EPS Information
| Current Quarter EPS Consensus Estimate | 0.83 |
| Current Year EPS Consensus Estimate | 3.49 |
| Estimated Long-Term EPS Growth Rate | 2.90 |
| Next EPS Report Date | 07/26/2013 |
Consensus Recommendations
| Current (1=Strong Buy, 5=Strong Sell) | 1.83 |
| 30 Days Ago | 1.81 |
| 60 Days Ago | 1.75 |
| 90 Days Ago | 1.75 |
Fundamental Ratios
P/E
| Current FY Estimate | 13.68 |
| Trailing 12 Months | 12.99 |
| PEG Ratio | 4.65 |
Price Ratios
| Price/Book | 2.60 |
| Price/Cash Flow | 7.77 |
| Price / Sales | 3.12 |
Current Ratio
| 03-31-13 | 1.87 |
| 12-31-12 | 1.90 |
| 09-30-12 | 2.32 |
Net Margin
| 03-31-13 | 14.10 |
| 12-31-12 | 14.09 |
| 09-30-12 | 14.16 |
Inventory Turnover
| 03-31-13 | 2.49 |
| 12-31-12 | 2.54 |
| 09-30-12 | 2.57 |
EPS Growth
| vs. Previous Year | -14.14% |
| vs. Previous Quarter | 2.41% |
ROE
| 03-31-13 | 19.88 |
| 12-31-12 | 20.53 |
| 09-30-12 | 21.17 |
Quick Ratio
| 03-31-13 | 1.51 |
| 12-31-12 | 1.54 |
| 09-30-12 | 1.89 |
Pre-Tax Margin
| 03-31-13 | 16.84 |
| 12-31-12 | 18.49 |
| 09-30-12 | 18.79 |
Debt-to-Equity
| 03-31-13 | 0.29 |
| 12-31-12 | 0.29 |
| 09-30-12 | 0.30 |
Sales Growth
| vs. Previous Year | -9.04% |
| vs. Previous Quarter | -9.09% |
ROA
| 03-31-13 | 10.64 |
| 12-31-12 | 11.09 |
| 09-30-12 | 11.53 |
Operating Margin
| 03-31-13 | 24.41 |
| 12-31-12 | 24.83 |
| 09-30-12 | 25.47 |
Book Value
| 03-31-13 | 18.40 |
| 12-31-12 | 18.24 |
| 09-30-12 | 19.11 |
Debt to Capital
| 03-31-13 | 22.44 |
| 12-31-12 | 22.66 |
| 09-30-12 | 23.19 |
